CinCor Pharma to Present at Upcoming Jefferies London Healthcare Conference
CinCor Pharma announced its participation at the Jefferies London Healthcare Conference from November 15-17, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CinCor Pharma announced its participation at the Jefferies London Healthcare Conference from November 15-17, 2022. The presentation is scheduled for November 16, 2022, at 5 PM GMT, at the Waldorf Hilton. CinCor will also engage in one-on-one investor meetings during the event. Founded in 2018, CinCor focuses on developing treatments for cardio-renal diseases, with its lead asset, baxdrostat, targeting hypertension and primary aldosteronism.
Details
News Market Reaction – CINC
The recorded move for CINC in the trading session of this news was -5.50%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the Jefferies London Healthcare Conference taking place on November 15-17, 2022 in London, United Kingdom. The presentation information is below:
| Jefferies London Healthcare Conference | |
| Presentation: | Wednesday, November 16, 2022 at 5 PM GMT |
| Location: | Track 2 – Room, Adelphi 2, Ground Level at the Waldorf Hilton |
The CinCor management team will participate in one-on-one investor meetings during the event. Investors interested in meeting with CinCor at the conference should contact their Jefferies representative.
About CinCor
CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat, a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.
| Contacts: | Investors: | |
| Mike Kalb | Bob Yedid | |
| CinCor Pharma, Inc. | LifeSci Advisors | |
| EVP and CFO | ir@CinCor.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.